Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

John Mascarenhas; Maria R. Baer; Craig Kessler; Elizabeth Hexner; Douglas Tremblay; Leah Price; Lonette Sandy; Rona Weinberg; Heike Pahl; Lewis R. Silverman; Judith D. Goldberg; Heidi Kosiorek; Amylou C. Dueck; Ronald Hoffman

doi:10.1080/10428194.2018.1532509

Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

John Mascarenhas, Maria R. Baer, Craig Kessler, Elizabeth Hexner, Douglas Tremblay, Leah Price, Lonette Sandy, Rona Weinberg, Heike Pahl, Lewis R. Silverman, Judith D. Goldberg, Heidi Kosiorek, Amylou C. Dueck, Ronald Hoffman

Research output: Contribution to journal › Letter › peer-review

15 Scopus citations

Original language	English
Pages (from-to)	1343-1345
Number of pages	3
Journal	Leukemia and Lymphoma
Volume	60
Issue number	5
DOIs	https://doi.org/10.1080/10428194.2018.1532509
State	Published - 16 Apr 2019

Access to Document

10.1080/10428194.2018.1532509

Cite this

@article{ca3b61d1b9e749dcbc4e30727f83221d,

title = "Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis",

author = "John Mascarenhas and Baer, {Maria R.} and Craig Kessler and Elizabeth Hexner and Douglas Tremblay and Leah Price and Lonette Sandy and Rona Weinberg and Heike Pahl and Silverman, {Lewis R.} and Goldberg, {Judith D.} and Heidi Kosiorek and Dueck, {Amylou C.} and Ronald Hoffman",

note = "Funding Information: This study was supported by the Myeloproliferative Disorders Research Consortium (MPD-RC) which is funded by the National Cancer Institute [P01CA108671]. Funding Information: This study was supported by the Myeloproliferative Disorders Research Consortium (MPD-RC) which is funded by the National Cancer Institute [P01CA108671]. Lestaurtinib was supplied to the MPD-RC for this trial by Teva pharmaceuticals.",

year = "2019",

month = apr,

day = "16",

doi = "10.1080/10428194.2018.1532509",

language = "English",

volume = "60",

pages = "1343--1345",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

AU - Mascarenhas, John

AU - Baer, Maria R.

AU - Kessler, Craig

AU - Hexner, Elizabeth

AU - Tremblay, Douglas

AU - Price, Leah

AU - Sandy, Lonette

AU - Weinberg, Rona

AU - Pahl, Heike

AU - Silverman, Lewis R.

AU - Goldberg, Judith D.

AU - Kosiorek, Heidi

AU - Dueck, Amylou C.

AU - Hoffman, Ronald

N1 - Funding Information: This study was supported by the Myeloproliferative Disorders Research Consortium (MPD-RC) which is funded by the National Cancer Institute [P01CA108671]. Funding Information: This study was supported by the Myeloproliferative Disorders Research Consortium (MPD-RC) which is funded by the National Cancer Institute [P01CA108671]. Lestaurtinib was supplied to the MPD-RC for this trial by Teva pharmaceuticals.

PY - 2019/4/16

Y1 - 2019/4/16

UR - http://www.scopus.com/inward/record.url?scp=85060643863&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1532509

DO - 10.1080/10428194.2018.1532509

M3 - Letter

C2 - 30668266

AN - SCOPUS:85060643863

SN - 1042-8194

VL - 60

SP - 1343

EP - 1345

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 5

ER -